Posted by cv6-admin
CV6 Therapeutics
Chris E. Rivera is currently the President, CEO and Chairman of the Board of Nativis Inc. He has over 30 years’ experience in the development and manufacturing of pharmaceutical and medical devices. Whilst at the Washington Biotechnology and Biomedical Association he established the commercialization programs of more than 400 emerging biotechnology companies. Chris was the […]
Posted by cv6-admin
CV6 Therapeutics
Richard (Dick) Milliken is a highly experienced business leader and financial executive with a distinguished career spanning senior roles across the life sciences, finance, and technology sectors. He served as Chairman of Catalyst Inc. (formerly the Northern Ireland Science Park) and the Lotus Group Ltd. and holds Non-Executive Director positions with Ryanair Plc and the […]
Posted by cv6-admin
CV6 Therapeutics
Paul Workman, PhD is Chief Executive and President of The Institute of Cancer Research (ICR), London. He is Harrap Professor of Pharmacology and Therapeutics at the ICR, as well as the former Head of the Division of Cancer Therapeutics and former Director of the Cancer Research UK Cancer Therapeutics Unit from 1997-2016. Paul is also […]
Posted by cv6-admin
CV6 Therapeutics
Ruth Plummer is Professor of Experimental Cancer Medicine at the Newcastle University and Director of the Sir Bobby Robson Cancer Trials Research Centre. She leads the Newcastle Experimental Cancer Medicine Centre and also the CRUK Newcastle Cancer Centre. Her research interests are in the field of DNA repair and early phase clinical trials of novel […]
Posted by cv6-admin
CV6 Therapeutics
Professor Patrick (Paddy) Johnston was a founding Board Member of CV6 Therapeutics and served as the Chairman of the Board of Directors from 2016 until his untimely passing in 2017. Paddy was a pioneer in the cancer research field, a truly inspirational and visionary leader who inspired those around him to ‘dream no little dreams’. […]
Posted by cv6-admin
CV6 Therapeutics
Jim Poliero is a licensed real estate broker and currently manages a private portfolio of income producing real estate, mortgages and equities. Mr. Poliero began his career with Commerce Bank (now known as TD Bank) and an affiliated real estate developer for 15 years where he served as a commercial loan officer, and specialized in […]
Posted by pbd-admin
CV6 Therapeutics
James Judson, ‘Jim’, served as a Board Member of CV6 Therapeutics from 2015 before stepping in as the Interim Chairman of the Board of Directors from June 2017 until his untimely passing on the 4th of January 2018. Jim was a trusted and valued member of the CV6 Team and will be deeply missed. We […]
Posted by pbd-admin
CV6 Therapeutics
Dr Melissa LaBonte Wilson joined the CV6 Therapeutics team in 2014 as a consultant in the biological validation of candidate small molecule inhibitors in our drug development pipeline. Melissa has over 14 years experience in the preclinical evaluation of small molecule and biologic-based cancer therapeutics having identified and characterized several first-in-class small-molecule and antibody-derived inhibitors […]
Posted by pbd-admin
CV6 Therapeutics
Dr. Lewis has over thirty years’ experience in the pharmaceutical industry discovering and developing novel small molecule and biological products for Merck & Co., and for Eisai Co., Ltd. While with Eisai, he most recently led the Pharmaceutical Sciences and Technology Core Function Unit (PST). PST performed chemical, manufacturing, and controls development at 10 sites […]
Posted by pbd-admin
CV6 Therapeutics
Richard Wilson, MD, is Professor in Gastrointestinal Oncology at the Institute of Clinical Sciences, University of Glasgow, and Honorary Consultant in Medical Oncology at the Beatson West of Scotland Cancer Centre. His clinical focus is on gastrointestinal cancers—primarily colorectal, as well as small bowel and peritoneal malignancies and he leads translational and biological research in […]
